Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial-Reference-Cited by-同舟云学术

Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial

Published:2021-01 Issue:1 Volume:9 Page:96-106
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Highland Kristin B,Distler Oliver,Kuwana Masataka,Allanore Yannick,Assassi Shervin,Azuma Arata,Bourdin Arnaud,Denton Christopher P,Distler Jörg H W,Hoffmann-Vold Anna Maria,Khanna Dinesh,Mayes Maureen D,Raghu Ganesh,Vonk Madelon C,Gahlemann Martina,Clerisme-Beaty Emmanuelle,Girard Mannaig,Stowasser Susanne,Zoz Donald,Maher Toby M

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference25 articles.

1. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative;van den Hoogen;Ann Rheum Dis,2013

2. Mapping and predicting mortality from systemic sclerosis;Elhai;Ann Rheum Dis,2017

3. Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort;Hoffmann-Vold;Am J Respir Crit Care Med,2019

4. Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis;Goh;Arthritis Rheumatol,2017

5. Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts;Volkmann;Ann Rheum Dis,2019

Cited by 138 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The 2024 British Society for Rheumatology guideline for management of systemic sclerosis;Rheumatology;2024-09-11

2. Development of a multivariable prediction model for progression of systemic sclerosis-associated interstitial lung disease;RMD Open;2024-09

3. Real-World Clinical Profile and Safety of Nintedanib in Systemic Sclerosis-Associated Interstitial Lung Disease: A Subgroup Analysis of Interstitial Lung Disease Data From an Interstitial Lung Disease (ILD) Specialty Clinic in India;Cureus;2024-07-28

4. Systemic sclerosis, silica exposure and cellular therapies: The sand in the gears?;La Revue de Médecine Interne;2024-07

5. Nintedanib combined with immunosuppressive agents improves forced vital capacity in connective tissue disease-associated PF-ILD: a single-center study;BMC Rheumatology;2024-06-18